Follow
'Discounts or rebates (a subcategory of so-called “managed entry agreements”) on drug prices are negotiated between governments and manufacturers, and a growing number are confidential.7 Confidential rebates are especially applied to cancer drugs.8 In consequence, countries using the external reference pricing system overestimate actual prices, triggering an upward spiral of drug prices.'
